Mizuho’s Jared Holz on Merck and Pfizer Q4 results, 2025 outlook for Big Pharma stocks

February 4, 2025
Mizuho’s Jared Holz on Merck and Pfizer Q4 results, 2025 outlook for Big Pharma stocksMizuho’s Jared Holz on Merck and Pfizer Q4 results, 2025 outlook for Big Pharma stocks

Jared Holz, Mizuho Securities America healthcare sector strategist, joins ‘Squawk Box’ to break down the quarterly earnings results of Merck and Pfizer, 2025 outlook for pharmaceutical stocks, and more.

Share This

Latest Mizuho News

See all news
Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

February 17, 2026
Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

February 23, 2026
Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

February 25, 2026

Mizuho news from around the globe

 Mizuho Global News
back-to-top-blue